| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 6, 2026 | ±4.4% | -16.4% | under-priced |
| February 4, 2026 | ±4.1% | +6.3% | under-priced |
| November 5, 2025 | ±3.4% | -1.9% | over-priced |
| May 8, 2025 | ±4.9% | +2.1% | over-priced |
| November 5, 2024 | ±4.7% | +2.3% | over-priced |
| May 6, 2024 | ±6.0% | -1.6% | over-priced |
| February 7, 2024 | ±4.6% | -1.5% | over-priced |
| November 7, 2023 | ±6.7% | +1.6% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q3 FY2026 | $0.32 | $311M | $51M |
| Q2 FY2026 | $0.24 | $296M | $38M |
| Q1 FY2026 | $0.24 | $287M | $38M |
| Q4 FY2025 | $-0.11 | $317M | $-18M |
Bio-Techne Corp. (TECH) reports in 98 days, with the next report estimated for September 19, 2026. Across the last 8 reports, options priced an average ±4.8% earnings move while the stock actually moved 4.2% on average — the market has systematically over-priced TECH's earnings risk. Fundamentals into the print: EPS up 128.6% year-over-year, revenue down 1.5%. QuantLogix's live 5-factor engine currently reads TECH as a buy at 52/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →